Etanercept treatment in juvenile idiopathic arthritis: The Polish registry

• DOI: 10.12659/msm.882109
• Publication Date: 2011-01-01
• Authors: Zbigniew Żuber; Lidia Rutkowska‐Sak; Jacek Postępski; Bogna Dobrzyniecka; Violetta Opoka‐Wi...; Katarzyna Kobusińska; Piotr Gietka; Violetta Osińska; Dorota Turowska-H...; Izabela Szczygielska; Beata Kołodziejczyk; Anna Świątek-Bacz...; Agnieszka Gazda; Piotr Wiland; Witold Tłustochowicz; Ewa Tuszkiewicz-M...
• Keywords: Combination therapy; Juvenile rheumatoid arthritis

To evaluate the long-term safety and efficacy of etanercept treatment in Polish patients with juvenile idiopathic arthritis (JIA).The study involved patients, fulfilling JIA criteria International League Associations Rheumatology (ILAR), who were started on therapy after methotrexate other synthetic disease-modifying antirheumatic drugs (DMARDs) had proven ineffective. Patient data collected an electronic registry. Disease improvement was assessed based Giannini's criteria.The statistical analysis 188 patients. Significant observed all clinical laboratory parameters first month maintained following months. ACR Pediatric 30, 50, 70, 90, 100 81.4%, 65.9%, 27.5%, 16.2%, 15%, respectively, 3 months 94.7%, 88.4%, 62.1%, 34.7%, 26.3%, 24 treatment. Throughout 72-month observation period, 1162 adverse events reported; exposure-adjusted AE rate 2.96 per patient year.In various subtypes resistant to conventional DMARD treatment, resulted significant long-lasting improvements disease activity. Combination a well tolerated.